Adaptive Bio Launches T-Cell Based COVID-19 Tests
- Adaptive Biotechnologies Corp (NASDAQ: ADPT) launched a clinical T-cell-based test kit to confirm recent or prior COVID-19 infection.
- T-Detect is currently under review by the FDA for Emergency Use Authorization.
- Separately, the Company also expanded its collaboration with Laboratory Corp. of America Holdings (NYSE: LH), which includes a commercial agreement for Adaptive's clonoSEQ and immunoSEQ assays, and a lab services agreement for Adaptive's recently launched T-Detect COVID test.
- As part of the expanded pact, patients can now have blood collection for both the clonoSEQ and T-Detect COVID tests at any Lab Corp patient service centers.
- Lab Corp will also offer immunoSEQ and immunoSEQ T-MAP COVID assays using Research Use Only test kits.
- Price Action: LH is up 1.3% at $247.24, while ADPT is down 4.20% at $54.34 in market trading hours on the last check Tuesday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Covid-19 testsBiotech News Health Care General
